Immune evasion in acute myeloid leukemia: current concepts and future directions (Q38172521)

30 August 2017

0 references

Immune evasion in acute myeloid leukemia: current concepts and future directions (English)

1 reference

evasion of host immune response

30 August 2017

1 reference

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

Ryan M Teague

1 reference

30 August 2017

Justin Kline

series ordinal

1 reference

30 August 2017

1 August 2013

1 reference

Journal for Immunotherapy of Cancer

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

Creative Commons Attribution 2.0 Generic

30 August 2017

start time

27 August 2013

1 reference

April 2022 Public Data File from Crossref

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Disseminating health information in developing countries: the role of the internet

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864190

Open access, impact, and demand

23 June 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864190

Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns

31 August 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Why do cancers have high aerobic glycolysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Targeting HLA class I expression to increase tumor immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Loss of mismatched HLA in leukemia after stem-cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Lymphoproliferation in CTLA-4–Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Role of LAG-3 in regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Prospects for TIM3-Targeted Antitumor Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Induced CD4+Foxp3+ regulatory T cells in immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

The inhibitory cytokine IL-35 contributes to regulatory T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Basic principles of tumor-associated regulatory T cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

CD40 ligation reverses T cell tolerance in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-1426-1-13

Expression of programmed death 1 ligands by murine T cells and APC

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.4049/JIMMUNOL.169.10.5538

Identifiers

DOI

10.1186/2051-1426-1-13

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference

30 August 2017

PubMed publication ID

24353898

1 reference